SURFACE ONCOLOGY INC (SURF) Fundamental Analysis & Valuation
NASDAQ:SURF • US86877M2098
Current stock price
1.07 USD
-0.01 (-0.93%)
At close:
1.07 USD
0 (0%)
After Hours:
This SURF fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. SURF Profitability Analysis
1.1 Basic Checks
- SURF had negative earnings in the past year.
- In the past year SURF has reported a negative cash flow from operations.
1.2 Ratios
- The profitability ratios for SURF are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- SURF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. SURF Health Analysis
2.1 Basic Checks
- SURF does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for SURF has been increased compared to 1 year ago.
- The debt/assets ratio for SURF is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -6.54, we must say that SURF is in the distress zone and has some risk of bankruptcy.
- SURF has a worse Altman-Z score (-6.54) than 72.65% of its industry peers.
- SURF has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.54 |
ROIC/WACCN/A
WACC9.86%
2.3 Liquidity
- SURF has a Current Ratio of 3.60. This indicates that SURF is financially healthy and has no problem in meeting its short term obligations.
- With a Current ratio value of 3.60, SURF is not doing good in the industry: 64.62% of the companies in the same industry are doing better.
- SURF has a Quick Ratio of 3.60. This indicates that SURF is financially healthy and has no problem in meeting its short term obligations.
- SURF has a worse Quick ratio (3.60) than 64.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.6 | ||
| Quick Ratio | 3.6 |
3. SURF Growth Analysis
3.1 Past
- The earnings per share for SURF have decreased strongly by -18.60% in the last year.
- Looking at the last year, SURF shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
- Measured over the past years, SURF shows a quite strong growth in Revenue. The Revenue has been growing by 18.57% on average per year.
EPS 1Y (TTM)-18.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-100%
Revenue growth 3Y24.89%
Revenue growth 5Y18.57%
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 5.56% on average over the next years.
- The Revenue is expected to grow by 21.55% on average over the next years. This is a very strong growth
EPS Next Y-41.08%
EPS Next 2Y-21.95%
EPS Next 3Y6.29%
EPS Next 5Y5.56%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-37.88%
Revenue Next 5Y21.55%
3.3 Evolution
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. SURF Valuation Analysis
4.1 Price/Earnings Ratio
- SURF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year SURF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.95%
EPS Next 3Y6.29%
5. SURF Dividend Analysis
5.1 Amount
- SURF does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SURF Fundamentals: All Metrics, Ratios and Statistics
1.07
-0.01 (-0.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-02 2023-08-02/bmo
Earnings (Next)10-31 2023-10-31/bmo
Inst Owners1.16%
Inst Owner Change-96.44%
Ins Owners18.04%
Ins Owner Change0%
Market Cap65.08M
Revenue(TTM)N/A
Net Income(TTM)-92.50M
Analysts76.36
Price Target2.43 (127.1%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.65%
Min EPS beat(2)-33.43%
Max EPS beat(2)10.13%
EPS beat(4)2
Avg EPS beat(4)-2.3%
Min EPS beat(4)-33.43%
Max EPS beat(4)18.07%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-54.6%
EPS NQ rev (1m)1.63%
EPS NQ rev (3m)-5.42%
EPS NY rev (1m)-11.28%
EPS NY rev (3m)-9.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.32 | ||
| P/tB | 1.32 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.53
EYN/A
EPS(NY)-1.59
Fwd EYN/A
FCF(TTM)-1.38
FCFYN/A
OCF(TTM)-1.37
OCFYN/A
SpS0
BVpS0.81
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 11.76% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.6 | ||
| Quick Ratio | 3.6 | ||
| Altman-Z | -6.54 |
F-Score2
WACC9.86%
ROIC/WACCN/A
Cap/Depr(3y)15.46%
Cap/Depr(5y)56.41%
Cap/Sales(3y)2.05%
Cap/Sales(5y)3.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-41.08%
EPS Next 2Y-21.95%
EPS Next 3Y6.29%
EPS Next 5Y5.56%
Revenue 1Y (TTM)-100%
Revenue growth 3Y24.89%
Revenue growth 5Y18.57%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-37.88%
Revenue Next 5Y21.55%
EBIT growth 1Y-42.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-372.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-371.18%
OCF growth 3YN/A
OCF growth 5YN/A
SURFACE ONCOLOGY INC / SURF Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for SURFACE ONCOLOGY INC?
ChartMill assigns a fundamental rating of 2 / 10 to SURF.
What is the valuation status for SURF stock?
ChartMill assigns a valuation rating of 0 / 10 to SURFACE ONCOLOGY INC (SURF). This can be considered as Overvalued.
Can you provide the profitability details for SURFACE ONCOLOGY INC?
SURFACE ONCOLOGY INC (SURF) has a profitability rating of 0 / 10.
Can you provide the financial health for SURF stock?
The financial health rating of SURFACE ONCOLOGY INC (SURF) is 5 / 10.